In the case of CTLA-4 inhibitors colitis is more likely; in the case of PD-1/PDL1 inhibitors pneumonitis, hepatitis and neurotoxicity are more likely; and in the case of combination therapy, colitis and myocarditis are more likely [19]. This evidence concerns the gene CD274 and Hepatitis.